182 related articles for article (PubMed ID: 19536894)
1. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Jain N; Reuben JM; Kantarjian H; Li C; Gao H; Lee BN; Cohen EN; Ebarb T; Scheinberg DA; Cortes J
Cancer; 2009 Sep; 115(17):3924-34. PubMed ID: 19536894
[TBL] [Abstract][Full Text] [Related]
2. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
Cathcart K; Pinilla-Ibarz J; Korontsvit T; Schwartz J; Zakhaleva V; Papadopoulos EB; Scheinberg DA
Blood; 2004 Feb; 103(3):1037-42. PubMed ID: 14504104
[TBL] [Abstract][Full Text] [Related]
3. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Smith BD; Kasamon YL; Kowalski J; Gocke C; Murphy K; Miller CB; Garrett-Mayer E; Tsai HL; Qin L; Chia C; Biedrzycki B; Harding TC; Tu GH; Jones R; Hege K; Levitsky HI
Clin Cancer Res; 2010 Jan; 16(1):338-47. PubMed ID: 20048335
[TBL] [Abstract][Full Text] [Related]
4. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
Sharma P; Kumar L; Mohanty S; Kochupillai V
Ann Hematol; 2010 Mar; 89(3):241-7. PubMed ID: 19714331
[TBL] [Abstract][Full Text] [Related]
5. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
6. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
Oji Y; Oka Y; Nishida S; Tsuboi A; Kawakami M; Shirakata T; Takahashi K; Murao A; Nakajima H; Narita M; Takahashi M; Morita S; Sakamoto J; Tanaka T; Kawase I; Hosen N; Sugiyama H
Eur J Haematol; 2010 Oct; 85(4):358-60. PubMed ID: 20633041
[TBL] [Abstract][Full Text] [Related]
7. Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India.
Sazawal S; Chhikara S; Singh K; Chaubey R; Mahapatra M; Seth T; Saxena R
Indian J Pathol Microbiol; 2019; 62(2):256-260. PubMed ID: 30971550
[TBL] [Abstract][Full Text] [Related]
8. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
10. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Bocchia M; Gentili S; Abruzzese E; Fanelli A; Iuliano F; Tabilio A; Amabile M; Forconi F; Gozzetti A; Raspadori D; Amadori S; Lauria F
Lancet; 2005 Feb 19-25; 365(9460):657-62. PubMed ID: 15721470
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
12. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
13. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
Goldman J
Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
[TBL] [Abstract][Full Text] [Related]
14. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic strategies in chronic myeloid leukemia.
Clark RE
Curr Hematol Malig Rep; 2007 May; 2(2):89-94. PubMed ID: 20425356
[TBL] [Abstract][Full Text] [Related]
17. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging.
Kreuzer KA; Klühs C; Baskaynak G; Movassaghi K; Dörken B; le Coutre P
Br J Haematol; 2004 Jan; 124(2):195-9. PubMed ID: 14687030
[TBL] [Abstract][Full Text] [Related]
18. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
Khazaal MS; Hamdan FB; Al-Mayah QS
Mol Genet Genomic Med; 2019 Aug; 7(8):e809. PubMed ID: 31206255
[TBL] [Abstract][Full Text] [Related]
19. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
20. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
